[go: up one dir, main page]

SE9700135D0 - New formulation - Google Patents

New formulation

Info

Publication number
SE9700135D0
SE9700135D0 SE9700135A SE9700135A SE9700135D0 SE 9700135 D0 SE9700135 D0 SE 9700135D0 SE 9700135 A SE9700135 A SE 9700135A SE 9700135 A SE9700135 A SE 9700135A SE 9700135 D0 SE9700135 D0 SE 9700135D0
Authority
SE
Sweden
Prior art keywords
new formulation
formulation
useful
treatment
dry powder
Prior art date
Application number
SE9700135A
Other languages
English (en)
Swedish (sv)
Inventor
Jan Trofast
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20405455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9700135(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9700135A priority Critical patent/SE9700135D0/xx
Publication of SE9700135D0 publication Critical patent/SE9700135D0/xx
Priority to ZA9878A priority patent/ZA9878B/xx
Priority to US09/004,902 priority patent/US6030604A/en
Priority to JP1998534218A priority patent/JP4512204B6/ja
Priority to AU57859/98A priority patent/AU731192B2/en
Priority to SK959-99A priority patent/SK283950B6/sk
Priority to BR9811249-0A priority patent/BR9811249A/pt
Priority to CNB988019000A priority patent/CN1271993C/zh
Priority to UA99074044A priority patent/UA57764C2/uk
Priority to HU0000714A priority patent/HU228622B1/hu
Priority to PL334527A priority patent/PL192115B1/pl
Priority to IL13083898A priority patent/IL130838A/xx
Priority to PT98901618T priority patent/PT1007017E/pt
Priority to ES98901618T priority patent/ES2235311T5/es
Priority to SI9830754T priority patent/SI1007017T2/sl
Priority to EP98901618A priority patent/EP1007017B2/fr
Priority to AT98901618T priority patent/ATE288260T1/de
Priority to IDW990663A priority patent/ID21865A/id
Priority to KR10-1999-7006414A priority patent/KR100528416B1/ko
Priority to TR1999/01690T priority patent/TR199901690T2/xx
Priority to EEP199900295A priority patent/EE03951B1/xx
Priority to DK98901618.3T priority patent/DK1007017T4/da
Priority to HK00104814.6A priority patent/HK1025515B/xx
Priority to CZ0255799A priority patent/CZ296301B6/cs
Priority to DE69828886T priority patent/DE69828886T3/de
Priority to RU99118587/14A priority patent/RU2194497C2/ru
Priority to NZ336594A priority patent/NZ336594A/xx
Priority to CA002277913A priority patent/CA2277913C/fr
Priority to PCT/SE1998/000040 priority patent/WO1998031352A1/fr
Priority to MYPI98000164A priority patent/MY132999A/en
Priority to ARP980100224A priority patent/AR011080A1/es
Priority to SA98180818A priority patent/SA98180818B1/ar
Priority to TW087103589A priority patent/TW557217B/zh
Priority to IS5108A priority patent/IS2788B/is
Priority to NO19993539A priority patent/NO327426B1/no
Priority to US09/431,916 priority patent/US6287540B1/en
Priority to JP2009255070A priority patent/JP2010059181A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9700135A 1997-01-20 1997-01-20 New formulation SE9700135D0 (sv)

Priority Applications (37)

Application Number Priority Date Filing Date Title
SE9700135A SE9700135D0 (sv) 1997-01-20 1997-01-20 New formulation
ZA9878A ZA9878B (en) 1997-01-20 1998-01-06 New formulation for inhalation
US09/004,902 US6030604A (en) 1997-01-20 1998-01-09 Formulation for inhalation
CA002277913A CA2277913C (fr) 1997-01-20 1998-01-13 Nouvelle formulation pour inhalation ayant une masse volumique apparente de 0,28 a 0,38 g/ml, procede de preparation et utilisation de cette formulation
PCT/SE1998/000040 WO1998031352A1 (fr) 1997-01-20 1998-01-13 Nouvelle formulation pour inhalation ayant une masse volumique apparente de 0,28 a 0,38 g/ml, procede de preparation et utilisation de cette formulation
IDW990663A ID21865A (id) 1997-01-20 1998-01-13 Formulasi untuk inhalasi yang mempunyai densitas ruah tertuang 0,28 sampai 0,38 g/ml, proses pembuatan dan penggunaannya
EEP199900295A EE03951B1 (et) 1997-01-20 1998-01-13 Inhaleeritav ravimvorm puistetihedusega 0,28 kuni0,38 g/ml, selle valmistamise protsess ja kasutamine
SK959-99A SK283950B6 (sk) 1997-01-20 1998-01-13 Inhalačná kompozícia, spôsob jej prípravy a jej použitie na prípravu liečiva
BR9811249-0A BR9811249A (pt) 1997-01-20 1998-01-13 Nova formulação para inalação; apresentando densidade volumétrica, quando derramada, de 0,20 à 0,38g/ml, processo para preparação de formulação e uso da mesma
CNB988019000A CN1271993C (zh) 1997-01-20 1998-01-13 注入堆积密度为0.28～0.38g/ml的吸入用新配方、该配方的制备方法及其用途
UA99074044A UA57764C2 (uk) 1997-01-20 1998-01-13 Суха порошкова композиція, спосіб її виготовлення та спосіб лікування
HU0000714A HU228622B1 (en) 1997-01-20 1998-01-13 Budesonide/formoterol formulation for inhalation having a poured bulk density of 0.30 to 0.36 g/ml, a process for preparing the formulation and the use thereof
PL334527A PL192115B1 (pl) 1997-01-20 1998-01-13 Sucha kompozycja proszkowa, sposób jej wytwarzania oraz jej zastosowanie
IL13083898A IL130838A (en) 1997-01-20 1998-01-13 Formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof
PT98901618T PT1007017E (pt) 1997-01-20 1998-01-13 Nova formulacao para inalacao possuindo uma massa volumica aparente de 0,28 a 0,38 g/ml, um processo para a sua preparacao formulacao e sua utilizacao
ES98901618T ES2235311T5 (es) 1997-01-20 1998-01-13 Formulación de budesónida/formoterol para inhalación que tiene una desidad aparente de vertido de 0,30 a 0,36 g/ml, un proceso para preparar la formulación y el uso de la misma.
SI9830754T SI1007017T2 (sl) 1997-01-20 1998-01-13 Budezonid/formoterol formulacija za inhaliranje, ki ima nasipno gostoto od 0,30 g/ml do 0,36 g/ml, postopek za pripravo formulacije in njena uporaba
EP98901618A EP1007017B2 (fr) 1997-01-20 1998-01-13 Budesonide / formoterol formulation pour inhalation ayant une masse volumique apparente de 0,30 a 0,36 g/ml, procede de preparation et utilisation de cette formulation
AT98901618T ATE288260T1 (de) 1997-01-20 1998-01-13 Neuartige formulierung zur inhalation mit einer bulkdichte zwischen 0.28 und 0.38 g/ml, verfahren zur herstellung der formulierung sowie anwendung derselben
JP1998534218A JP4512204B6 (ja) 1997-01-20 1998-01-13 ０．２８から０．３８ｇ／ｍｌのかさ密度を有する吸入用新規製剤、その製剤を調製する方法およびその使用
KR10-1999-7006414A KR100528416B1 (ko) 1997-01-20 1998-01-13 0.28 내지 0.38 ｇ/㎖의 유동 벌크 밀도를 갖는 신규 흡입 제제, 그의 제조 방법 및 그의 용도
TR1999/01690T TR199901690T2 (xx) 1997-01-20 1998-01-13 Yeni solunum form�lasyonu, form�lasyonu haz�rlamaya y�nelik i�lem.
AU57859/98A AU731192B2 (en) 1997-01-20 1998-01-13 New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof
DK98901618.3T DK1007017T4 (da) 1997-01-20 1998-01-13 Formulering af budesonid/formoterol til inhalering, som har en hældebulkdensitet på 0,30 til 0,36 g/ml, en fremgangsmåde til fremstilling af formuleringen og anvendelsen deraf
HK00104814.6A HK1025515B (en) 1997-01-20 1998-01-13 New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof
CZ0255799A CZ296301B6 (cs) 1997-01-20 1998-01-13 Suchý práskový prostredek, zpusob jeho prípravy alécivo s jeho obsahem
DE69828886T DE69828886T3 (de) 1997-01-20 1998-01-13 Neuartige formulierung zur inhalation mit einer bulkdichte zwischen 0.28 und 0.38 g/ml, verfahren zur herstellung der formulierung sowie anwendung derselben
RU99118587/14A RU2194497C2 (ru) 1997-01-20 1998-01-13 Новый препарат для ингаляции, имеющий насыпную объемную плотность от 0,28 до 0,38 г/мл, способ его получения и его применение
NZ336594A NZ336594A (en) 1997-01-20 1998-01-13 Formulation for inhalation which includes a carrier (lactose, glucose, raffinose, melezitose, lactitol, trehalose, sucrose, mannitol or starch
MYPI98000164A MY132999A (en) 1997-01-20 1998-01-15 New formulation for inhalation
ARP980100224A AR011080A1 (es) 1997-01-20 1998-01-19 Composicion en polvo seco, proceso para su preparacion y uso de dicha composicion para la fabricacion del medicamento
SA98180818A SA98180818B1 (ar) 1997-01-20 1998-02-10 صياغة جديدة للاستنشاق
TW087103589A TW557217B (en) 1997-01-20 1998-03-11 Pharmaceutical dry powder compositions for use in treating respiratory disorders and the process for preparing the same
IS5108A IS2788B (is) 1997-01-20 1999-07-06 Búdesóníð- / formóterólefnablanda til innöndunar með lausa þéttni frá 0,30 til 0,36 g/ml, aðferð við að framleiða efnablönduna og notkun hennar
NO19993539A NO327426B1 (no) 1997-01-20 1999-07-19 Torrpulverpreparat, fremgangsmate for fremstilling samt anvendelse av nevnte preparat
US09/431,916 US6287540B1 (en) 1997-01-20 1999-11-02 Formulation for inhalation
JP2009255070A JP2010059181A (ja) 1997-01-20 2009-11-06 ０．２８から０．３８ｇ／ｍｌのかさ密度を有する吸入用新規製剤、その製剤を調製する方法およびその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9700135A SE9700135D0 (sv) 1997-01-20 1997-01-20 New formulation

Publications (1)

Publication Number Publication Date
SE9700135D0 true SE9700135D0 (sv) 1997-01-20

Family

ID=20405455

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9700135A SE9700135D0 (sv) 1997-01-20 1997-01-20 New formulation

Country Status (34)

Country Link
US (2) US6030604A (fr)
EP (1) EP1007017B2 (fr)
JP (1) JP2010059181A (fr)
KR (1) KR100528416B1 (fr)
CN (1) CN1271993C (fr)
AR (1) AR011080A1 (fr)
AT (1) ATE288260T1 (fr)
AU (1) AU731192B2 (fr)
BR (1) BR9811249A (fr)
CA (1) CA2277913C (fr)
CZ (1) CZ296301B6 (fr)
DE (1) DE69828886T3 (fr)
DK (1) DK1007017T4 (fr)
EE (1) EE03951B1 (fr)
ES (1) ES2235311T5 (fr)
HU (1) HU228622B1 (fr)
ID (1) ID21865A (fr)
IL (1) IL130838A (fr)
IS (1) IS2788B (fr)
MY (1) MY132999A (fr)
NO (1) NO327426B1 (fr)
NZ (1) NZ336594A (fr)
PL (1) PL192115B1 (fr)
PT (1) PT1007017E (fr)
RU (1) RU2194497C2 (fr)
SA (1) SA98180818B1 (fr)
SE (1) SE9700135D0 (fr)
SI (1) SI1007017T2 (fr)
SK (1) SK283950B6 (fr)
TR (1) TR199901690T2 (fr)
TW (1) TW557217B (fr)
UA (1) UA57764C2 (fr)
WO (1) WO1998031352A1 (fr)
ZA (1) ZA9878B (fr)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
AU1786199A (en) * 1998-12-11 2000-07-03 Pharmachemie B.V. Pharmaceutical preparation for inhalation of an opioid
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
AR022695A1 (es) * 1999-01-28 2002-09-04 Schering Corp PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
US6623760B1 (en) * 1999-01-28 2003-09-23 Schering Corporation Method of preparing particles for agglomeration
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
HK1042234A1 (zh) * 1999-04-13 2002-08-09 Nektar Therapeutics 向肺部施加乾粉配方以治疗不育症
CA2273585A1 (fr) 1999-05-28 2000-11-28 Canpolar East Inc. Capteurs servant a detecter les changements de temperature, le ph, les conditions chimiques, les conditions biologiques, les radiations, le champ electrique et la pression
IL146886A0 (en) 1999-06-05 2002-08-14 Innovata Biomed Ltd Medicament delivery system
GB9920839D0 (en) 1999-09-04 1999-11-10 Innovata Biomed Ltd Inhaler
DE19962926A1 (de) * 1999-12-24 2001-06-28 Bayer Ag Verfahren zur Co-Mahlung von Stoffen und Lactose mittels Strahlmühlen
US6369115B1 (en) * 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
CA2405599A1 (fr) * 2000-04-13 2001-10-25 Innovata Biomed Limited Medicaments contenant du formoterol et de la fluticasone, destines au traitement de troubles respiratoires
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
US20020076382A1 (en) * 2000-08-04 2002-06-20 Kaplan Leonard W. Formulations of mometasone and a bronchodilator for pulmonary administration
FI20002177A0 (fi) * 2000-10-02 2000-10-02 Orion Yhtymae Oyj Uusi yhdistelmä astman hoitoon
FI20002216A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
JP5154732B2 (ja) * 2001-02-06 2013-02-27 イノバータ・バイオメッド・リミテッド 薬剤
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
TWI324934B (en) * 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
US7931022B2 (en) 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
GB0128148D0 (en) 2001-11-23 2002-01-16 Innovata Biomed Ltd Assembly
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
WO2003094967A2 (fr) * 2002-05-07 2003-11-20 Altana Pharma Ag Nouvelle combinaison destinee au traitement des troubles des voies aeriennes
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
GB0219512D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
EP1599209B1 (fr) * 2002-08-21 2011-08-17 Norton Healthcare Limited Compositions a inhaler
CA2500065A1 (fr) * 2002-09-30 2004-04-15 Acusphere, Inc. Liberation reguliere de microparticules poreuses a inhaler
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
WO2004052374A1 (fr) * 2002-12-12 2004-06-24 Altana Pharma Ag Medicament combine
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
EP1452179A1 (fr) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Nouveau combination d'un puissant agoniste beta 2 de longue duree et un corticosteroid
US20040191176A1 (en) * 2003-03-28 2004-09-30 Kaplan Leonard W Formulations for treatment of pulmonary disorders
WO2004103379A1 (fr) * 2003-05-22 2004-12-02 Altana Pharma Ag Combinaison de salmeterol et ciclesonide
SE527200C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av formaterol och fluticason
SE527189C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel
SE527190C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
SE526850C2 (sv) * 2003-06-19 2005-11-08 Microdrug Ag Farmaceutisk kombinerad torr pulverdos separerade på gemensam dosbädd
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
GB0316335D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
WO2005020963A1 (fr) 2003-09-02 2005-03-10 Ivax Corporation Procede de preparation d'un medicament
PL1670482T5 (pl) * 2003-09-16 2022-10-03 Covis Pharma Gmbh Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
OA13362A (en) * 2004-01-22 2007-04-13 Pfizer Sulfonamide derivatives for the treatment of diseases.
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
AR048339A1 (es) * 2004-03-24 2006-04-19 Chiesi Farma Spa Monoclorhidrato de 8- hidroxi-5-((1r)) -1- hidroxi-2- (((1r)-2 ( 4-metoxifenil) -1- metiletil) amino ) eti l) -2 (1h) - quinolinona en form acristalina y el proceso para su preparacion
CA2563556C (fr) * 2004-04-20 2013-01-29 Altana Pharma Ag Utilisation de ciclesonide pour le traitement des maladies respiratoires chez des patients fumeurs
BRPI0509348A (pt) 2004-04-21 2007-09-11 Innovata Biomed Ltd inalador
GB0409197D0 (en) 2004-04-24 2004-05-26 Innovata Biomed Ltd Device
KR20070100735A (ko) * 2004-12-17 2007-10-11 씨아이피엘에이 엘티디. 약학적 화합물 및 조성물
US9365905B2 (en) * 2005-02-10 2016-06-14 Dmv-Fonterra Excipients Technology Gmbh Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
PL1921919T3 (pl) 2005-07-14 2012-09-28 Lithera Inc Ulepszona lipolityczna formulacja o podtrzymywanym uwalnianiu do traktowania lokalnej tkanki tłuszczowej
EP1904219A4 (fr) * 2005-07-15 2011-07-27 Map Pharmaceuticals Inc Procede de formation de particules
AU2006269961B2 (en) * 2005-07-15 2012-07-19 Map Pharmaceuticals, Inc. Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
US20070148211A1 (en) * 2005-12-15 2007-06-28 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
US20070178166A1 (en) * 2005-12-15 2007-08-02 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
PL2077830T3 (pl) * 2006-10-17 2013-04-30 Lithera Inc Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
WO2008100727A2 (fr) 2007-02-14 2008-08-21 The Trustees Of Columbia University In The City Of New York Glycine à haute dose comme traitement de troubles obsessionnels compulsifs et de troubles du spectre obsessionnel compulsif
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
DE102007049931A1 (de) 2007-10-18 2009-04-23 Pharmatech Gmbh Vorrichtung und Verfahren zur kontinuierlichen Herstellung von sphärischen Pulveragglomeraten
US20100120737A1 (en) * 2008-11-10 2010-05-13 Martin Feth Amorphous ciclesonide
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
KR20190049943A (ko) * 2009-05-29 2019-05-09 펄 테라퓨틱스 인코포레이티드 활성제의 호흡기 전달
WO2011088413A2 (fr) * 2010-01-15 2011-07-21 Lithera, Inc. Préparations pour gâteaux lyophilisés
WO2011110852A1 (fr) 2010-03-10 2011-09-15 Astrazeneca Ab Formes polymorphes de l'éthylamide de l'acide 6-[2-(4-cyanophényl)-2h-pyrazol-3-yl]-5-méthyl-3-oxo-4-(trifluorométhylphényl)-3,4-dihydropyrazine-2-carboxylique
MX2013004137A (es) 2010-10-12 2013-07-29 Cipla Ltd Composicion farmaceutica.
EP2646012A4 (fr) 2010-11-24 2014-12-10 Neothetics Inc Formulations monothérapeutiques d'agonistes bêta sélectifs, lipophiles et à action prolongée, et procédés de traitement cosmétique de l'adiposité et du renflement de la silhouette
CN104271112A (zh) 2012-04-11 2015-01-07 希普拉有限公司 包含阿福特罗和糠酸氟替卡松的药物组合物
RU2510267C2 (ru) * 2012-06-15 2014-03-27 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
EP2968152B2 (fr) 2013-03-15 2022-06-22 Pearl Therapeutics, Inc. Procedes et systemes de conditionnement de matieres cristallines particulaires
PT2821061T (pt) 2013-07-01 2018-03-13 Arven Ilac Sanayi Ve Ticaret As Novas formulações para inalação
EP3668505A4 (fr) 2017-08-15 2021-05-12 Nephron Pharmaceuticals Corporation Composition de nébulisation aqueuse
WO2020240350A1 (fr) * 2019-05-24 2020-12-03 Glenmark Pharmaceutical Limited Composition de poudre inhalable à dose fixe comprenant du glycopyrronium, du formotérol et du propionate de fluticasone

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4161516A (en) † 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
CY1492A (en) * 1981-07-08 1990-02-16 Draco Ab Powder inhalator
SE438261B (sv) * 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
DE3268533D1 (en) * 1981-07-24 1986-02-27 Fisons Plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
GB8825541D0 (en) † 1988-11-01 1988-12-07 Fisons Plc Formulation
ATE138814T1 (de) * 1989-04-28 1996-06-15 Riker Laboratories Inc Inhalationsvorrichtung für trockenpulver
US5176132A (en) * 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
DK0441740T3 (da) † 1990-01-29 1993-11-08 Ciba Geigy Ag Fremgangsmåde og apparat til dosering af et firkornet pulver
US5192548A (en) * 1990-04-30 1993-03-09 Riker Laboratoires, Inc. Device
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
SE9100342D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroid esters
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU2017592A (en) * 1991-06-10 1993-01-12 Schering Corporation Non-chlorofluorocarbon aerosol formulations
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
WO1993011773A1 (fr) * 1991-12-18 1993-06-24 Aktiebolaget Astra Nouvelle combinaison de formoterol et de budesonide
US5355872B1 (en) * 1992-03-04 1998-10-20 John H Riggs Low flow rate nebulizer apparatus and method of nebulization
ES2177544T3 (es) † 1992-06-12 2002-12-16 Teijin Ltd Polvo ultrafinno para inhalar y metodo para su preparacion.
WO1994008568A1 (fr) * 1992-10-16 1994-04-28 Nippon Shinyaku Co., Ltd. Procede pour fabriquer des matrices de cire
DE69415677T2 (de) * 1993-08-18 1999-06-10 Unilever N.V., Rotterdam Rasiermittel
IS1736B (is) * 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
EG20677A (en) † 1993-10-01 1999-11-30 Astra Ag Method and an apparatus for micronizing the particle size
GB9404945D0 (en) † 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US5647347A (en) * 1994-10-21 1997-07-15 Glaxo Wellcome Inc. Medicament carrier for dry powder inhalator
US5503869A (en) * 1994-10-21 1996-04-02 Glaxo Wellcome Inc. Process for forming medicament carrier for dry powder inhalator
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
SE9603669D0 (sv) * 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation

Also Published As

Publication number Publication date
EP1007017B2 (fr) 2010-12-08
SI1007017T1 (en) 2005-06-30
CA2277913A1 (fr) 1998-07-23
PL192115B1 (pl) 2006-08-31
ES2235311T5 (es) 2011-03-31
RU2194497C2 (ru) 2002-12-20
JP4512204B2 (ja) 2010-07-28
US6287540B1 (en) 2001-09-11
IL130838A0 (en) 2001-01-28
NO993539L (no) 1999-09-20
ID21865A (id) 1999-08-05
DE69828886T3 (de) 2011-06-01
CA2277913C (fr) 2007-03-06
TR199901690T2 (xx) 1999-09-21
EE9900295A (et) 2000-02-15
CZ255799A3 (cs) 1999-10-13
HU228622B1 (en) 2013-04-29
US6030604A (en) 2000-02-29
AU731192B2 (en) 2001-03-29
UA57764C2 (uk) 2003-07-15
DK1007017T3 (da) 2005-05-02
CN1243436A (zh) 2000-02-02
TW557217B (en) 2003-10-11
NZ336594A (en) 2001-01-26
KR20000070188A (ko) 2000-11-25
SA98180818B1 (ar) 2006-03-25
DE69828886D1 (de) 2005-03-10
KR100528416B1 (ko) 2005-11-16
BR9811249A (pt) 2000-09-05
IS2788B (is) 2012-06-15
ES2235311T3 (es) 2005-07-01
NO327426B1 (no) 2009-06-29
AR011080A1 (es) 2000-08-02
DK1007017T4 (da) 2011-02-28
EP1007017B1 (fr) 2005-02-02
AU5785998A (en) 1998-08-07
NO993539D0 (no) 1999-07-19
ATE288260T1 (de) 2005-02-15
PL334527A1 (en) 2000-02-28
SK283950B6 (sk) 2004-05-04
IL130838A (en) 2005-07-25
HUP0000714A2 (hu) 2000-08-28
EP1007017A1 (fr) 2000-06-14
SI1007017T2 (sl) 2011-03-31
WO1998031352A1 (fr) 1998-07-23
PT1007017E (pt) 2005-05-31
ES2235311T8 (es) 2011-05-13
DE69828886T2 (de) 2006-04-06
MY132999A (en) 2007-10-31
CN1271993C (zh) 2006-08-30
JP2010059181A (ja) 2010-03-18
ZA9878B (en) 1998-07-20
SK95999A3 (en) 2000-01-18
CZ296301B6 (cs) 2006-02-15
HK1025515A1 (en) 2000-11-17
JP2001508793A (ja) 2001-07-03
HUP0000714A3 (en) 2000-10-30
EE03951B1 (et) 2003-02-17
IS5108A (is) 1999-07-06

Similar Documents

Publication Publication Date Title
SE9700135D0 (sv) New formulation
SE9700133D0 (sv) New formulation
SE9700134D0 (sv) New formulation
SE9700136D0 (sv) New formulation